Citation map · Study

SZodixStudyAcademic Library

Shelves Open access

Study · an open academic library·Metadata from OpenAlex (CC0)·Shelves·OpenAlex metadata, de-duplicated

Higher US Branded Drug Prices And Spending Compared To Other Countries May Stem Partly From Quick Uptake Of New Drugs

9 references·3 citing·47 second hop

FromToDepth

this work references cited by second hop

References

1992Brand Loyalty, Entry, and Price Competition in Pharmaceuticals after the 1984 Drug Act574 cited
2000Cross-national price differences for pharmaceuticals: how large, and why?285 cited
1997Generic Entry and the Pricing of Pharmaceuticals260 cited
2003Prices And Availability Of Pharmaceuticals: Evidence From Nine Countries199 cited
2008International Prices And Availability Of Pharmaceuticals In 2005170 cited
2013Managed entry agreements for pharmaceuticals: the European experience167 cited
2007Generic entry, price competition, and market segmentation in the prescription drug market161 cited
2008Competition in off-patent drug markets: Issues, regulation and evidence140 cited
2004Price Competition in Pharmaceuticals: The Case of Anti‐infectives118 cited

Cited by

2017Older Americans Were Sicker And Faced More Financial Barriers To Health Care Than Counterparts In Other Countries89 cited
2018Differential Pricing of Pharmaceuticals: Theory, Evidence and Emerging Issues64 cited
2021Evaluation of Drug Trials in High-, Middle-, and Low-Income Countries and Local Commercial Availability of Newly Approved Drugs60 cited

Only edges whose both ends are imported exist here. Widen the year window, or show the whole map. Back to the work